stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

PTC Therapeutics, Inc.

United States 路 NASDAQ:聽PTCT 路 Market cap: 路 P/E: 路 P/S:

PTC Therapeutics makes and sells medicines for rare genetic disorders, including Duchenne muscular dystrophy, to patients and distributors around the world.

PTC Therapeutics is a biopharmaceutical company that develops and sells medicines for people with rare and often devastating genetic disorders. Its best-known work is in Duchenne muscular dystrophy, a muscle-wasting disease that mostly strikes boys and slowly robs them of the ability to walk, breathe, and live independently. PTC sells treatments for this disease to patients and distributors internationally, and it has built a portfolio that also reaches other rare conditions, including certain metabolic and neurological disorders.

The business is not a household name because its customers are not everyday shoppers. They are patients, doctors, and the distributors and health systems that pay for specialty drugs, often at very high prices per patient. That is the core economics of rare disease: small patient populations, enormous development costs, and prices that can run into hundreds of thousands of dollars per year. PTC earns money by selling these medicines, and a big part of its revenue comes from outside the United States, where it sells through distributors rather than building its own sales force in every country. The Duchenne field is crowded and scientifically tricky. PTC competes with other drugmakers working on the same disease, including Sarepta Therapeutics, and its therapies have faced tough regulatory reviews and payer pushback over whether the benefit justifies the cost. That tension is the heart of the investment story: promising science, fragile reimbursement, and a company that must keep proving its drugs are worth paying for. PTC spends heavily on research and development, which is why it has often reported losses even while growing sales.


What makes PTC interesting is its mix of risk and reach. It has a broad pipeline and global commercial footprint, but it also carries debt and depends on a handful of key products and regulatory wins. Its shares have swung wildly on trial results and approval decisions, a reminder that in rare disease biotech, a single yes or no from a regulator can reshape the whole company.

Saved answer 路 last researched 15 Nov 2026